Legacy Financial Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.98M | Sell |
9,093
-51
| -0.6% | -$11.3K | 0.28% | 61 |
|
|
2025
Q4 | $2.09M | Sell |
9,144
-283
| -3% | -$64.5K | 0.29% | 59 |
|
|
2025
Q3 | $2.18M | Sell |
9,427
-44
| -0.5% | -$8.96K | 0.3% | 54 |
|
|
2025
Q2 | $1.76M | Sell |
9,471
-407
| -4% | -$75.6K | 0.27% | 58 |
|
|
2025
Q1 | $2.07M | Buy |
9,878
+470
| +5% | +$91.4K | 0.35% | 47 |
|
|
2024
Q4 | $1.67M | Buy |
9,408
+272
| +3% | +$50K | 0.28% | 60 |
|
|
2024
Q3 | $1.8M | Buy |
9,136
+400
| +5% | +$74.7K | 0.3% | 56 |
|
|
2024
Q2 | $1.5M | Sell |
8,736
-84
| -1% | -$13.9K | 0.27% | 62 |
|
|
2024
Q1 | $1.61M | Buy |
8,820
+401
| +5% | +$69.1K | 0.29% | 60 |
|
|
2023
Q4 | $1.3M | Buy |
8,419
+505
| +6% | +$73.6K | 0.25% | 67 |
|
|
2023
Q3 | $1.18M | Buy |
7,914
+1,581
| +25% | +$232K | 0.24% | 58 |
|
|
2023
Q2 | $853K | Sell |
6,333
-1,724
| -21% | -$253K | 0.16% | 76 |
|
|
2023
Q1 | $1.28M | Buy |
8,057
+827
| +11% | +$126K | 0.26% | 45 |
|
|
2022
Q4 | $1.17M | Buy |
7,230
+1,660
| +30% | +$255K | 0.25% | 47 |
|
|
2022
Q3 | $748K | Buy |
5,570
+745
| +15% | +$107K | 0.18% | 63 |
|
|
2022
Q2 | $739K | Sell |
4,825
-536
| -10% | -$81.9K | 0.18% | 62 |
|
|
2022
Q1 | $869K | Buy |
5,361
+1,374
| +34% | +$200K | 0.2% | 55 |
|
|
2021
Q4 | $540K | Buy |
3,987
+213
| +6% | +$25.2K | 0.12% | 85 |
|
|
2021
Q3 | $407K | Sell |
3,774
-331
| -8% | -$37.8K | 0.1% | 98 |
|
|
2021
Q2 | $462K | Sell |
4,105
-654
| -14% | -$73.7K | 0.12% | 79 |
|
|
2021
Q1 | $515K | Buy |
4,759
+158
| +3% | +$16.9K | 0.14% | 65 |
|
|
2020
Q4 | $491K | Buy |
4,601
+415
| +10% | +$39.9K | 0.14% | 61 |
|
|
2020
Q3 | $367K | Buy |
+4,186
| New | +$394K | 0.11% | 69 |
|
|
2020
Q1 | – | Sell |
-3,454
| Closed | -$306K | – | 56 |
|
|
2019
Q4 | $306K | Sell |
3,454
-45
| -1% | -$3.74K | 0.1% | 97 |
|
|
2019
Q3 | $265K | Sell |
3,499
-150
| -4% | -$10.3K | 0.09% | 96 |
|
|
2019
Q2 | $265K | Buy |
3,649
+14
| +0.4% | +$1.1K | 0.09% | 99 |
|
|
2019
Q1 | $293K | Sell |
3,635
-251
| -6% | -$20.5K | 0.1% | 90 |
|
|
2018
Q4 | $358K | Sell |
3,886
-96
| -2% | -$8.44K | 0.14% | 65 |
|
|
2018
Q3 | $376K | Sell |
3,982
-57
| -1% | -$5.41K | 0.14% | 61 |
|
|
2018
Q2 | $390K | Buy |
4,039
+20
| +0.5% | +$1.95K | 0.15% | 62 |
|
|
2018
Q1 | $376K | Buy |
4,019
+71
| +2% | +$7.8K | 0.15% | 65 |
|
|
2017
Q4 | $381K | Buy |
+3,948
| New | +$372K | 0.16% | 58 |
|
Other funds holding ABBV
VCM
VPM
Legacy Financial Advisors's ABBV Position: Q1 2026 in Review
Legacy Financial Advisors reduced its AbbVie (ABBV) stake by 0.56% in Q1 2026, selling an estimated $11.3K and leaving 9,093 shares worth $1.98M. The position accounts for 0.28% of the portfolio, ranked #61.
Legacy Financial Advisors first reported a position in ABBV in Q4 2017 and has held it in 32 quarters since. The position peaked at $2.18M in Q3 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Legacy Financial Advisors held 9,093 shares of AbbVie worth $1.98M as of Q1 2026.
- Legacy Financial Advisors sold 51 AbbVie shares in Q1 2026, an estimated $11.3K.
- AbbVie made up 0.28% of Legacy Financial Advisors's portfolio in Q1 2026, its #61 holding.
- Legacy Financial Advisors first reported a position in AbbVie in Q4 2017 and has held it in 32 quarters since.
- Legacy Financial Advisors's AbbVie position peaked at $2.18M in Q3 2025.
- 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Legacy Financial Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.